Merck Serono
Merck Serono is Merck KGaA's Healthcare business unit, operating as EMD Serono in North America. It develops prescription medicines, medical devices, and digital health solutions across rare tumors, oncology, multiple sclerosis, fertility, endocrinology, and general medicine, with global fertility market leadership.
- Company typePrivate
- Founded1987
- HeadquartersDarmstadt, Germany
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Merck Serono does
Merck Serono is the Healthcare business unit of Merck KGaA, Darmstadt, Germany, operating under the EMD Serono brand in the United States and Canada. The company develops and commercializes prescription medicines, medical devices, and digital health solutions across six therapeutic areas: Rare Tumors (desmoid tumors, neurofibromatosis type 1, tenosynovial giant cell tumor), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, and lung cancers), Neurology and Immunology (multiple sclerosis with over 20 years of experience), Fertility (where it claims global market leadership), Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid disorders). Core technologies include biomarker-based personalized treatment matching, mRNA platforms, self-injection devices paired with disease monitoring software for MS patients, and patient-directed digital solutions built with patient input for care beyond the clinic.
The business operates on a prescription pharmaceutical model, selling primarily through direct sales relationships with hospitals, clinics, and healthcare providers globally. Distribution is supported by regional subsidiaries (e.g., EMD Serono in the US/Canada) and a dedicated clinical trial supply subsidiary (Merck KGaA Export GmbH), reaching patients across Africa, Asia, Europe, Latin America, North America, and Oceania. Pricing for prescription pharmaceuticals is not publicly disclosed. Merck Serono is one of three business sectors of Merck KGaA, Darmstadt, Germany, alongside Life Science (MilliporeSigma) and Electronics (EMD Electronics); however, revenue figures are not disclosed at the business-unit level in the available data.
Recent activity in 2026 includes the dosing of the first patient in a Phase 3 study of Precem-TcT for metastatic colorectal cancer (May 2026), a collaboration with Versant Ventures to launch Saturnus Bio focused on rare genetic cardiomyopathies (June 2026), and leadership changes including the appointment of Monia Vial as President of EMD Serono and Miguel Fernández Alcalde as Head of Global Commercial Strategy (June 2026).
Merck Serono firmographics
Firmographics- Name
- Merck Serono
- Legal name
- Merck KGaA, Darmstadt, Germany
- Website
- https://biopharma.merckgroup.com
- Company type
- Private
- Founded year
- 1987
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Merck Serono is Merck KGaA's Healthcare business unit, operating as EMD Serono in North America. It develops prescription medicines, medical devices, and digital health solutions across rare tumors, oncology, multiple sclerosis, fertility, endocrinology, and general medicine, with global fertility market leadership.
- Ownership category
- akta.pro rank
Merck Serono industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)
Keywords
Where Merck Serono is headquartered
LocationHeadquarters
- HQ city
- Darmstadt
- HQ country
- Germany
- HQ region
- Europe
Markets served
Merck Serono business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Distribution channels3 records
Marketing channels6 records
Merck Serono product offering
Product offeringCore offering
Merck Serono develops, manufactures, and commercializes prescription medicines and associated medical devices across six therapeutic areas: Rare Tumors (desmoid tumors, NF1, TGCT), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, and lung cancers), Neurology & Immunology (Multiple Sclerosis), Fertility, Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid). It complements medicines with intelligent self-injection devices and disease monitoring software, particularly for MS, and leverages biomarker matching and mRNA technology to enable personalized treatment.
Product overview
Merck Serono (EMD Serono in North America) operates as the Healthcare business of Merck KGaA, Darmstadt, Germany, offering a portfolio of medicines, medical devices, and digital health solutions across six therapeutic areas: Rare Tumors (desmoid tumors, NF1, TGCT), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, lung cancers), Neurology & Immunology (Multiple Sclerosis with injection devices and monitoring software), Fertility (treatments and IVF technologies), Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid). The company uses a patient-directed approach, integrating digital solutions built with patient input, and operates as part of a tri-business structure alongside Life Science and Electronics.
Differentiator
Problem solved
Functional benefit
Brands
- Vibrant Thoughts: Blog featuring science and technology perspectives on disease understanding and patient innovation
- The Future Transformation
Products and services
- Rare Tumors medicines
Companies that use Merck Serono
Customer profileSegments6 records
Ideal customer profiles5 records
Merck Serono technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Merck Serono partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights4 records
Merck Serono competitors and assessment
Company assessmentDirect peers
- Astellas Pharma: Japanese biopharma with strong rare-disease and oncology focus, including work in rare tumors. Comparable therapeutic-area mix and emerging oncology pipeline strategy.
- Sanofi: Large biopharma with rare-disease focus via Genzyme, MS franchise (Lemtrada, Aubagio), and fertility exposure via its consumer health division. Comparable breadth across Merck Serono's therapeutic areas.
- Novartis: Global biopharma with overlapping portfolios in neurology/MS, oncology, and women's health/reproductive medicine. Direct competitor in MS and fertility, and active in biomarker-driven oncology.
- Vertex Pharmaceuticals: Specialized biopharma focused on serious diseases including rare genetic disorders. Comparable precision-medicine approach and growing rare-disease franchise relevant to Merck Serono's Saturnus Bio initiative.
- Ipsen: Specialty biopharma with rare-disease and oncology focus, including treatments in neurofibromatosis and other rare tumors. Most direct comparable to Merck Serono's rare-tumors franchise.
- Biogen: Pure-play neurology/neuroscience biopharma with leading MS franchise (Tysabri, Tecfidera). Direct MS competitor with similar focus on neuro-immunology and chronic disease management.
- Roche: Swiss-headquartered biopharma with deep oncology and biomarker-driven diagnostics franchises (Roche Diagnostics/Genentech), directly comparable in personalized oncology strategy and global reach.
Broad incumbents
- Pfizer: Global pharmaceutical incumbent with broad oncology, neurology, and rare-disease portfolios. Overlaps in oncology pipeline and MS competitor presence, with broader scale and commercial reach.
- Bristol-Myers Squibb: Major oncology-focused biopharma with deep immuno-oncology pipeline. Competes with Merck Serono's biomarker-driven oncology strategy across multiple solid tumor indications.
- Bayer: German-headquartered life sciences company with pharmaceutical division spanning women's health, oncology, and cardiovascular. Comparable in therapeutic-area breadth and European commercial footprint.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Merck Serono social profiles
Digital presenceMerck Serono financial estimates
Financial estimateRevenue estimate
Valuation estimate
Merck Serono leadership team
Management profileNumber of profiles
Profiles2 records
Merck Serono subsidiaries and ownership
Company hierarchySubsidiaries4 records
Merck Serono funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Merck Serono M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Merck Serono
What does Merck Serono do?
Merck Serono develops, manufactures, and commercializes prescription medicines and associated medical devices across six therapeutic areas: Rare Tumors (desmoid tumors, NF1, TGCT), Oncology (Merkel Cell Carcinoma, head and neck, colorectal, and lung cancers), Neurology & Immunology (Multiple Sclerosis), Fertility, Endocrinology (growth hormone deficiency), and General Medicine (diabetes, cardiovascular, thyroid). It complements medicines with intelligent self-injection devices and disease monitoring software, particularly for MS, and leverages biomarker matching and mRNA technology to enable personalized treatment.
Is Merck Serono a public or private company?
Merck Serono is a private company. It is classified as corporate owned and is currently operating.
When was Merck Serono founded?
Merck Serono was founded in 1987. It employs 5,001 to 10,000 people.
Where is Merck Serono based?
Merck Serono is headquartered in Darmstadt, Germany, in the Europe region.
Who are Merck Serono's main competitors?
Direct peers on record are Astellas Pharma, Sanofi, Novartis, Vertex Pharmaceuticals, Ipsen, Biogen and Roche. Broad incumbents are Pfizer, Bristol-Myers Squibb and Bayer.
Does Merck Serono have an API?
No public API is recorded for Merck Serono.
What industry is Merck Serono in?
Merck Serono's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAJ, Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health), with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 325412 and its SIC code is 2834.